General
Preferred name
DEFEROXAMINE
Synonyms
DEFEROXAMINE MESYLATE ()
Deferoxamine B ()
desferrioxamine B ()
Desferrioxamine B mesylate ()
DFOM ()
Desferioxamine mesylate ()
Deferoxamine (mesylate) ()
Deferoxamine mesylate (Ba 33112) ()
Desferrioxamine B, DFOM, NSC 644468 ()
Deferriferrioxamine B ()
Deferrioxamine ()
Desferrioxamine Mesylate ()
Desferrioxamine Mesilate ()
Desferal ()
NSC-756718 ()
Deferoxamini mesilas ()
Deferoxamine Mesilate ()
BA-33112 ()
Deferoxamine methanesulfonate ()
Dfo-b ()
Desferrioxamine ()
NSC-527604 ()
Desferoxamine b ()
Deferoxamina ()
BA-29837 ()
Desferrioxamine hydrochloride ()
NSC-268993 ()
Deferoxamine hcl ()
DEFEROXAMINE HYDROCHLORIDE ()
P&D ID
PD009835
CAS
138-14-7
70-51-9
1950-39-6
Tags
available
drug
drug candidate
Approved by
FDA
First approval
1968
Drug indication
intracerebral hemorrhage
Acute iron or aluminum toxicity
Beta-thalassemia
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1?? levels and induces apoptosis.
DESCRIPTION
Deferoxamine (Deferoxamine B) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine upregulates HIF-1¦Á levels with good antioxidant activity. Deferoxamine also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].
PRICE
284
DESCRIPTION
Deferoxamine(Desferrioxamine B) is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1?? production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases.
DESCRIPTION
Deferoxamine mesylate, an iron chelator, could be used in the treatment of acute iron poisoning, sickle cell diseases and it is also found to have some extent of antioxidant effects.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Deferoxamine(Desferrioxamine B) is an iron chelator (binds Fe(III) and many other metal cations) that inhibits neuronopathy, may be used to modify the reduction of iron accumulation and deposition in tissues, and may improve neurological dysfunction by inhibiting ferroptosis and neuroinflammation following traumatic brain injury.Desferrioxamin-B has antioxidant, antiproliferative, Deferoxamine has antioxidant, antiproliferative, and antitumor activities, and can induce HIF-1α production, apoptosis and autophagy in cancer cells.Desferrioxamin-B can be used in the treatment of acute iron toxicity and COVID-19 related diseases.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
14
Organisms
3
Compound Sets
22
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
143
Molecular Weight
560.35
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
6
Rotatable Bonds
23
Ring Count
0
Aromatic Ring Count
0
cLogP
0.92
TPSA
205.84
Fraction CSP3
0.8
Chiral centers
0.0
Largest ring
0.0
QED
0.06
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Amyloid-¦Â
Amyloid-??Autophagy
Akt
HIF/HIF Prolyl-Hydroxylase
Reactive Oxygen Species (ROS)
Autophagy,Beta Amyloid,Ferroptosis,HIF
Reactive Oxygen Species
antioxidant
HIF
Amyloid-β
Iron
Mitophagy
Pathway
Angiogenesis
Apoptosis
Autophagy
Chromatin/Epigenetic
oxidation-reduction
Metabolism
Neuroscience
Immunology/Inflammation
Metabolic Enzyme/Protease
NF-κB
PI3K/Akt/mTOR
NF-¦ÊB
MOA
Ferroptosis
chelating agent
Indication
acute iron intoxication, iron overload
Solubility
H2O: ≥ 33 mg/mL
Source data

